Beyond omnichannel: Why pharma commercialisation must shift ...
We need to step away from the passive, broad concept of omnichannel and adopt a far more active, disciplined framework: omnideployment.
Newsletters and Deep Dive digital magazine
We need to step away from the passive, broad concept of omnichannel and adopt a far more active, disciplined framework: omnideployment.
With AI, trial sponsors are now reducing risk, accelerating timelines, and driving innovation by modelling what is most likely to work in the future.
How can pharma lead the way in ethical AI and trust-driven innovation?
As investors place increasing emphasis on operational maturity alongside scientific excellence, cyber resilience must become part of the conversation.
Unfortunately, much of the discussion around the JCA has focused on how the framework is intended to operate, rather than how it works in practice.
Editor's Picks
Newsletters and Deep Dive
digital magazine